These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 14723109)
1. Inflammation: a unifying theory for the origin of dry eye syndrome. Wilson SE Manag Care; 2003 Dec; 12(12 Suppl):14-9. PubMed ID: 14723109 [TBL] [Abstract][Full Text] [Related]
5. Lacrimal punctum occlusion in the treatment of severe keratoconjunctivitis Sicca caused by Sjögren syndrome: a uniocular evaluation. Mansour K; Leonhardt CJ; Kalk WW; Bootsma H; Bruin KJ; Blanksma LJ; Cornea; 2007 Feb; 26(2):147-50. PubMed ID: 17251802 [TBL] [Abstract][Full Text] [Related]
6. Severe, unilateral, unresponsive keratoconjunctivitis sicca in 16 juvenile Yorkshire Terriers. Herrera HD; Weichsler N; Gómez JR; de Jalón JA Vet Ophthalmol; 2007; 10(5):285-8. PubMed ID: 17760706 [TBL] [Abstract][Full Text] [Related]
7. [Lacrimation blocking technique in the treatment of severe "dry eye" syndrome]. Senchikhin MV Vestn Oftalmol; 2005; 121(4):39-41. PubMed ID: 16223044 [No Abstract] [Full Text] [Related]
8. Immunopathogenesis of keratoconjunctivitis sicca in the dog. Williams DL Vet Clin North Am Small Anim Pract; 2008 Mar; 38(2):251-68, vi. PubMed ID: 18299006 [TBL] [Abstract][Full Text] [Related]
9. Ophthalmic cyclosporine (Restasis) for dry eye disease. Med Lett Drugs Ther; 2003 May; 45(1157):42-3. PubMed ID: 12766701 [No Abstract] [Full Text] [Related]
10. Guidelines for the treatment of chronic dry eye disease. Sheppard JD Manag Care; 2003 Dec; 12(12 Suppl):20-5. PubMed ID: 14723110 [TBL] [Abstract][Full Text] [Related]
11. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation. Cordero-Coma M; Anzaar F; Sobrin L; Foster CS Ocul Immunol Inflamm; 2007; 15(2):99-104. PubMed ID: 17558834 [TBL] [Abstract][Full Text] [Related]
12. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Barber LD; Pflugfelder SC; Tauber J; Foulks GN Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833 [TBL] [Abstract][Full Text] [Related]
13. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. Stonecipher K; Perry HD; Gross RH; Kerney DL Curr Med Res Opin; 2005 Jul; 21(7):1057-63. PubMed ID: 16004673 [TBL] [Abstract][Full Text] [Related]
14. [Effect of anti-inflammatory therapy on the treatment of dry eye syndrome]. Mrukwa-Kominek E; Rogowska-Godela A; Gierek-Ciaciura S Klin Oczna; 2007; 109(1-3):79-84. PubMed ID: 17687921 [TBL] [Abstract][Full Text] [Related]
15. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Lee HK; Ryu IH; Seo KY; Hong S; Kim HC; Kim EK Ophthalmology; 2006 Feb; 113(2):198-205. PubMed ID: 16360211 [TBL] [Abstract][Full Text] [Related]
16. [Efficacy of hyaluronic acid eyedrops in the treatment of dry eye. Cytologic study using an optical microscope and computerized microscope]. Orsoni JG; Chiari M; Guazzi A; de Carli M; Guidolin D Ophtalmologie; 1988 Oct; 2(4):355-7. PubMed ID: 3247208 [No Abstract] [Full Text] [Related]
17. The management of dry eye. Drug Ther Bull; 2016 Jan; 54(1):9-12. PubMed ID: 26763598 [TBL] [Abstract][Full Text] [Related]
18. ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice. Gao J; Morgan G; Tieu D; Schwalb TA; Luo JY; Wheeler LA; Stern ME Exp Eye Res; 2004 Apr; 78(4):823-35. PubMed ID: 15037117 [TBL] [Abstract][Full Text] [Related]
19. Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Conjunctival Staining in Patients with Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and 3 Clinical Trials. Smyth-Medina R; Johnston J; Devries DK; Jasper A; Kannarr SR; Schechter BA; Shen Lee B; Varghese G; Ogundele A; Darby CH; Karpecki P; Luchs J J Ocul Pharmacol Ther; 2019 Sep; 35(7):388-394. PubMed ID: 31373837 [No Abstract] [Full Text] [Related]